Company news
Corcept Therapeutics Incorporated news in 2024
Corcept Therapeutics Incorporated's news releases, calls and decks from 2024, newest first.
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
December 29, 2024
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
December 15, 2024
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
December 11, 2024
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
December 10, 2024
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
October 29, 2024
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 21, 2024
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
June 23, 2024
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
June 2, 2024
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
May 27, 2024
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
April 30, 2024
Corcept Completes Enrollment in Phase 4 CATALYST Trial
April 28, 2024
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 23, 2024
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
April 21, 2024
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
April 14, 2024
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
April 7, 2024
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
March 31, 2024
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
February 14, 2024
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
February 14, 2024
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
February 7, 2024
Corcept Appoints Roberto Vieira as President, Oncology
January 28, 2024
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
January 7, 2024
Calls in 2024
- Corcept Therapeutics (NASDAQ:CORT) Q3 2024 Earnings Call
Oct 30, 2024
Transcript - Corcept Therapeutics (NASDAQ:CORT) Q2 2024 Earnings Call
Jul 29, 2024
Transcript - Corcept Therapeutics (NASDAQ:CORT) Q1 2024 Earnings Call
May 1, 2024
Transcript - Corcept Therapeutics (NASDAQ:CORT) Q4 2023 Earnings Call
Feb 15, 2024
Transcript
Decks in 2024
- Technical Presentation (December 2024)
Technical · 15 slides · Dec 12, 2024
- 22nd World Congress on Insulin Resistance, Diabetes, & Cardiovascular Disease 2024
Conference · 15 slides · December 2024